Skip to content

Released Mar 30, 2023, after the close

10-K filed Mar 30, 2023, 89 days after period end · 0000950170-23-010921

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$278.00Kderivedno prior Q4 2021 on file−74.3% vs Q3 2022
Net Income$26.79MderivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$25,924,000N/M
Operating Cash Flowderived$44,482,000N/M
Margins · derived
Operating margin9325.2%
Net margin9634.9%

What the release said

The release

Same quarter

MetricQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figuresQ4 2019
Revenue$278.00K—$0.00$696.00K
Net Income$26.79M-$29.30M-$18.60M-$24.99M
EPS Diluted———-$1.31

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR